CAR-T Therapy in Clinical Practice: Technical Advances and Current Challenges

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• CAR-T cell therapy has revolutionized cancer treatment, with approved products for certain leukemias and lymphomas.
• Despite successes, limitations such as relapse, poor solid tumor efficacy, toxicity, and resistance hinder broader application.
• Hundreds of CAR-T clinical trials are ongoing, reflecting intense research interest and development.

Purpose of the Study:

• To review antigens, CAR designs, and cell sources used in CAR-T clinical trials from 2020-2021.
• To discuss innovative modular and programmable CAR-T cell designs.
• To explore strategies for enhancing CAR-T cell versatility, efficacy, persistence, and safety.

Main Methods:

• Review of clinical trials data from 2020-2021 focusing on CAR-T therapy.
• Analysis of advancements in CAR design, including signaling and antigen-recognition domains.
• Discussion of T cell engineering and cell resource innovations.

Main Results:

• Summarized key antigens, CAR designs, and cell sources in recent CAR-T trials.
• Highlighted innovative modular and programmable CAR designs.
• Identified genetic and chemical engineering as promising strategies for improvement.

Conclusions:

• Multidisciplinary approaches are crucial for overcoming CAR-T therapy limitations.
• Next-generation CAR-T therapies hold promise for patients refractory to standard treatments.
• Advancements in CAR design and engineering are key to improving therapeutic outcomes.